VINCERX PHARMA INC. - COMMON STOCK

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

28 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 мар 2023 16:35:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

06 фев 2023 08:00:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

13 дек 2022 09:29:13 Источник Nasdaq GlobeNewswire

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

12 дек 2022 16:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

11 дек 2022 10:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

10 ноя 2022 16:05:02 Источник Nasdaq GlobeNewswire

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

03 ноя 2022 09:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

11 авг 2022 16:05:01 Источник Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

10 июн 2022 08:00:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Provides Key Strategic Update

06 июн 2022 16:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

12 май 2022 16:05:02 Источник Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 апр 2022 13:05:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

29 мар 2022 08:00:03 Источник Nasdaq GlobeNewswire

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

08 мар 2022 16:35:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

09 фев 2022 08:00:01 Источник Nasdaq GlobeNewswire

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

03 фев 2022 08:30:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

17 дек 2021 08:00:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

11 дек 2021 15:30:00 Источник Nasdaq GlobeNewswire

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

07 дек 2021 08:00:01 Источник Nasdaq GlobeNewswire